Verify member benefits and government policy overrides

Coverage and other determinations apply only when the service is a covered benefit for the member at the time of request; Medicare and Medicaid policies (LCD/NCD and state Medicaid rules) supersede this policy when in conflict. Providers should verify member benefits and applicable government policies before proceeding.

• Application of criteria depends on individual benefit coverage at request time
• Government policies (LCD/NCD) supersede when in conflict

Use applicable CPT/HCPCS codes for diagnostic tests

Use the policy's listed CPT/HCPCS procedure codes when submitting claims for diagnostic testing; these codes may be used in billing and prior authorization reviews and payer processes.

• Applicable CPT/HCPCS codes listed in section VIII (see chunks 34–35)
• Government policies or LCD/NCD may override payer coding requirements

No prior authorization rules specified here — confirm with payer

This excerpt does not list any specific prior authorization requirements or identify which services require preauthorization. Providers should follow member benefit documents and payer-specific prior authorization processes.

• Policy section shown provides evidence and guidance but no explicit prior auth rules in these chunks
• Check member benefit documents and payer portals for prior authorization requirements

Choose therapy informed by diagnostic confirmation

Select antifungal therapy based on diagnostic confirmation and clinical context; treatment options include topical agents, oral antifungals, and other modalities noted in guidelines.

• Therapies include topical agents (tavaborole, efinaconazole), oral antifungals (terbinafine, itraconazole, fluconazole), and adjunctive therapies (laser, iontophoresis)
• If nail matrix is involved, consider combining systemic and topical therapy

Empiric terbinafine may be used if testing cost-prohibitive

AAFP states empiric terbinafine can be considered when testing is cost prohibitive; however, laboratory confirmation is generally recommended before initiating treatment.

• AAFP: "Diagnostic testing is generally recommended before initiating treatment, but empiric treatment with terbinafine can be considered if testing is cost prohibitive."
• Accurate diagnosis requires identification of physical changes and positive laboratory analysis

No step-therapy rules specified in this section

No step therapy or sequencing requirements are specified in these policy excerpts. Providers should follow clinical judgment and payer-specific utilization management rules if present.

• Policy excerpts do not define step therapy algorithms or required treatment sequences
• Follow payer-specific rules where applicable

Document clinical findings and mycologic confirmation

Providers must submit accurate documentation and appropriate coding for services performed; an onychomycosis diagnosis should be supported by clinical findings and mycological laboratory results.

• Submit documentation according to industry standards (CPT, ICD-10, UB, CMS/NCCI rules)
• Diagnosis should be based on clinical exam plus mycological lab results (KOH, culture, PAS, PCR as appropriate)

Collect and document appropriate nail specimens prior to testing

Follow guideline specimen collection recommendations and document collection technique: clean the nail with 70% isopropyl alcohol and obtain subungual debris and multiple nail clippings from the most proximal area of onycholysis.

• Clean nail with 70% isopropyl alcohol prior to collection (AAFP guidance)
• Obtain subungual debris and multiple nail clippings from the most proximal area of onycholysis
• Document specimen source and collection method in the medical record

Include confirmatory lab test results and literature-based rationale

Retain and attach supporting diagnostic documentation referenced in guidelines and evidence when submitting claims: KOH microscopy, fungal culture, PAS histology, and when used, PCR or sequencing results.

• Cite KOH, culture, PAS as core confirmatory tests per BAD, AAFP, and cited literature
• If PCR/NAAT used (eg, after therapy failure), include test results and rationale

Risk of claim denial or recoupment for incorrect coding or documentation

Claims may be denied or recouped if coding/billing guidelines, current reimbursement policies, or documentation requirements are not followed; ensure correct codes and supporting documentation are submitted.

• Failure to follow coding/billing guidelines or provide accurate documentation may result in denial or recoupment
• Use the listed CPT/HCPCS codes and document medical necessity and test results

No additional provider actions in this excerpt

This specific section of the document does not include additional actionable items beyond those already stated in these provider actions.

• No further provider actions are present in these chunks

No explicit denial triggers listed here

No explicit denial triggers are present in these chunks beyond general coding/documentation risks; follow documentation and coding rules to reduce denial risk.

• No specific denial triggers listed in these excerpts
• Adhere to documentation and coding guidance to avoid denials